Crossbeta gains new ceo and funding

Dutch biotech to advance technology in several therapeutic areas

Crossbeta gains new ceo and funding
Crossbeta Biosciences, based in Utrecht in The Netherlands has appointed Guus Scheefhals as chief executive.

Scheefhals has joined the biotech firm from Avantium, where he held several managerial positions, most recently as chief operating officer of the pharma business unit. Prior to Avantium, he held commercial positions at DSM Biologics, Analytico and NPBI, which is now part of Fresenius.

Scheefhals replaces Johan Renes, who steps down after being with the company from the start and for the past two years as part-time ceo.

Crossbeta has recently won funding of €2m, which will be used to advance the firm’s technology in several therapeutic areas and to establish a stronger position for co-development programmes and commercialisation partnerships.

You may also like

Research & Development

Probiodrug and Crossbeta Biosciences enter into a partnership in the field of Alzheimer’s disease biomarkers

Licensing and supply agreement is based on Crossbeta’s proprietary technology and supports Probiodrug’s biomarker development activities
Regulatory
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Research & Development
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset

BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset

The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
Regulatory
What is ISO/IEC 17025 and why it matters for calibration

What is ISO/IEC 17025 and why it matters for calibration

As regulatory expectations continue to increase, particularly around data integrity and traceability, the question becomes less about collecting data, and more about trusting it
Regulatory
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development

NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development

The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development
Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration

Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration

Mabion has signed a letter of intent with Oddifact to reposition its Phase III-stage CD20 monoclonal antibody candidate for rare disease indications, leveraging AI-driven orphan drug identification and existing manufacturing expertise
Subscribe now